From Health Affairs Today <[email protected]>
Subject Impact of 340B Drug Program on Oncology Services
Date July 3, 2023 8:05 PM
  Links have been removed from this email. Learn more in the FAQ.
  Links have been removed from this email. Learn more in the FAQ.
 

View Message in Browser <[link removed]>

[link removed]

 

[link removed]

 

[link removed]

 

[link removed]

 

[link removed]

Monday, July 3, 2023 | The Latest Research, Commentary, And News From
Health Affairs

 

The premium cost for oncology drugs is a burden for many patients,
especially those living in rural communities. Today, Kelsey Owsley and
Cathy Bradley examine the 340B Drug Pricing Program as a way for rural
area hospitals to increase access to oncology services.

 

Oncology in Rural Areas

Rural areas experience significant gaps in access to oncology services
and providers. Hospitals in rural areas cite the high cost of cancer
treatments and services as barriers to providing oncology services.

This is the context in which Kelsey Owsley and Cathy Bradley explore the
340B Drug Pricing Program, a program which "allows eligible
not-for-profit and public hospitals to purchase covered outpatient
drugs, including high-cost oncology drugs, at discounted prices."

The coauthors of the article, released earlier this month in Health
Affairs, examine the drug program's impact on the incorporation of
oncology services into rural hospitals
<[link removed]>.

Owsley and Bradley find that those rural hospitals without oncology
services that joined the 340B Drug Pricing Program were more likely to
begin providing oncology services by 2020 than those hospitals that did
not join the program.
For more on the paper's findings, listen to Kelsey Owsley and
Editor-in-Chief Alan Weil on A Health Podyssey.
<[link removed]>

Read the Article
<[link removed]>


 

Elsewhere at Health Affairs

Today in Health Affairs Forefront, Eli Adashi and colleagues argue for
the codification of FDA's oversight of laboratory-developed tests.
<[link removed]>


 

Daily Digest

To Protect Patients And Spark Innovation, Codify The FDA's Oversight
Of Laboratory-Developed Tests
<[link removed]>

Eli Adashi et al.

Access To Oncology Services In Rural Areas: Influence Of The 340B Drug
Pricing Program
<[link removed]>

Kelsey Owsley and Cathy Bradley

 

About Health Affairs

Health Affairs is the leading peer-reviewed journal
<[link removed]> at the intersection of health,
health care, and policy. Published monthly by Project HOPE, the journal
is available in print and online. Late-breaking content is also found
through healthaffairs.org <[link removed]>, Health
Affairs Today <[link removed]>, and Health
Affairs Sunday Update <[link removed]>.  

Project HOPE <[link removed]> is a global health and
humanitarian relief organization that places power in the hands of local
health care workers to save lives across the globe. Project HOPE has
published Health Affairs since 1981.

Copyright © Project HOPE: The People-to-People Health Foundation, Inc.

Health Affairs, 1220 19th Street, NW, Suite 800, Washington, DC 20036, United States

Privacy Policy <[link removed]>

To unsubscribe from this email, update your email preferences here
<[link removed]>.
_________________

Sent to [email protected]

Unsubscribe:
[link removed]

Health Affairs, 1220 19th Street, NW, Suite 800, Washington, DC 20036, United States
Screenshot of the email generated on import

Message Analysis